Last reviewed · How we verify
PQ912 oral
At a glance
| Generic name | PQ912 oral |
|---|---|
| Also known as | varoglutamstat, Varoglutamstat, Glutaminyl Cyclase Inhibitor |
| Sponsor | Vivoryon Therapeutics N.V. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease (PHASE2)
- Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PQ912 oral CI brief — competitive landscape report
- PQ912 oral updates RSS · CI watch RSS
- Vivoryon Therapeutics N.V. portfolio CI